Company intelligence / Profile preview

AcuityBio

Newton, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

AcuityBio is a clinical-stage biotechnology company developing site-specific drug delivery systems to prevent the recurrence of solid tumors after surgery. The company's lead product, ABC110, is a drug-eluting surgical wrap that delivers cisplatin directly to the site of lung cancer resection to target residual microscopic disease. This localized approach aims to improve efficacy while reducing the systemic side effects associated with traditional chemotherapy. The technology is based on a proprietary bio-absorbable polymer platform developed at Boston University.

Therapeutic areas: Oncology
Modalities: Small moleculePolymer-drug conjugate therapy
Industry: Biotech

Beyond the preview

Go deeper on AcuityBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AcuityBio.

Explore the full profile